An intensive audit on 250 patients of advanced ovarian cancer to improve quality of care in a tertiary referral oncology centre in India

M. D. Ray; S. V. S. Deo; Raja Pramanik; Premanand N.

doi:10.18203/2320-1770.ijrcog20222468

Authors

M. D. Ray Department of Surgical Oncology, IRCH, AIIMS, New Delhi, India http://orcid.org/0000-0002-7059-5383
S. V. S. Deo Department of Surgical Oncology, IRCH, AIIMS, New Delhi, India
Raja Pramanik Department of Surgical Oncology, IRCH, AIIMS, New Delhi, India
Premanand N. Department of Surgical Oncology, IRCH, AIIMS, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20222468

Keywords:

Ovarian cancer, CRS, HIPEC, DFS, Clinical audit

Abstract

Background: A clinical audit provides the framework to improve the quality of patient care in a systematic way. In this study, we intensively audited our 250 advanced epithelial ovarian cancer (EOC) patients aiming to improve our patient care.

Methods: Ambispective study of 250 patients of advanced EOC was done from our prospectively maintained computerized database in the department of surgical oncology, AIIMS, New Delhi from 2013 to 2020.We audited the demographic profile, treatment patterns, perioperative and survival outcomes in different subgroups.

Results: In this study, 83.6% stage III and 16.4% stage IV A. There was 62 (24.8%) upfront, 112 (44.8%) interval and 76 (30.4%) secondary group. 126 underwent cytoreductive surgery (CRS) and 124 CRS and hyperthermic intraperitoneal chemotherapy (HIPEC). There was 24.8% early and 8.4% late postop complications. Median follow up 50 months. Overall, the median disease-free survival (DFS) 39 months. PFS was 12 months among 68 patients with recurrence. Attrition rate 4%. In the upfront setting, the median DFS 44 months in CRS only group and DFS not reached (p=0.032) in CRS and HIPEC group still. In the interval setting, the median DFS 39 months in CRS only group and 44 months in CRS and HIPEC group (p=0.06). In recurrent setting, the median DFS 14 months in CRS group and 23 months in CRS and HIPEC group (p=0.02)

Conclusions: Audit is an integral part of any clinical practice. It teaches us to improve the quality of care and thereby better outcomes. We recommend 6 monthly clinical audits in any cancer treatment for better outcomes in future.

Metrics

Metrics Loading ...

References

National Cancer Institute; Surveillance, Epidemiology, and End Results [SEER] Program. Globocan fact sheets: ovary cancer. 2018.

Bercow AS, Chen A, Chatterjee S. Cost of Care for the Initial Management of Ovarian Cancer. Obstet Gynecol. 2017;130(6):1269-75.

Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40:1213-23.

McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-63

McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on newdevelopments and pathogenesis. Pathology. 2011;43:420-32.

Jesus E. Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan and Korea. Cancer J. 2009;15(3):249-54.

DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology-Annual Advances in Oncology, Lippincott Williams and Wilkins. 2010;1:188-93.

Casado-Adam A, Alderman R, Stuart OA, Chang D, Sugarbaker PH. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011;2011:468698.

Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863-9.

Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106(5):1144-53.

Hansson J, Graf W, Pahlman L, Nygren P, Mahteme H. Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2009;35(2):202-8.

Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxomaperitonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54(3):293-9.

Preti V, Chang D, Sugarbaker PH. Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients. Gastroenterol Res Pract. 2012;2012:635314.

Sugarbaker P, Van der Speeten K, Stuart O, Chang D, Mahteme H. Patient-and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Sugarbaker PH, editor. Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. Connecticut: Cine-Med. 2012.

Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J SurgOncol. 2007;96(2):102-12.

Chereau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E et al. Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG. 2009;116(8):1062-8.

Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W. Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol. 2008;109(2):303-7.

Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94(11):1408-14.

Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J. 2009;15(3):196-9.

Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermicchemoperfusion. Ann Surg Oncol. 2004;11(4):387-92.

Muller H, Hahn M, Weller L, Simsa J. Strategies to reduce perioperative morbidity in cytoreductive surgery. Hepato-Gastroenterol. 2008;55(86-87):1523-9.

Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36(10):1486-91.

Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435-43.

Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426-32.

Vukadinovic V, Chiou JD, Morris DL. Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (HIPEC), a single center experience. Eur J Surg Oncol. 2015;41(5):702-6.

Chicago Consensus Working Group. The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction. Cancer. 2020;126(11):2510-2.

Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230-40.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570-5.

Kim SI, Cho J, Lee EJ. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(50):e18355.